Purple Biotech Ltd. Statistics
Share Statistics
Purple Biotech Ltd. has 2.58M shares outstanding. The number of shares has increased by -92.93% in one year.
| Shares Outstanding | 2.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -93.71% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.56M |
| Failed to Deliver (FTD) Shares | 9.79K |
| FTD / Avg. Volume | 1.09% |
Short Selling Information
The latest short interest is 19.52K, so 0.98% of the outstanding shares have been sold short.
| Short Interest | 19.52K |
| Short % of Shares Out | 0.98% |
| Short % of Float | 0.99% |
| Short Ratio (days to cover) | 0.43 |
Valuation Ratios
The PE ratio is -1016.97 and the forward PE ratio is -1.28.
| PE Ratio | -1016.97 |
| Forward PE | -1.28 |
| PS Ratio | 103.25 |
| Forward PS | null |
| PB Ratio | 0.59 |
| P/FCF Ratio | -1.01 |
| PEG Ratio | n/a |
Enterprise Valuation
Purple Biotech Ltd. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.2, with a Debt / Equity ratio of 0.
| Current Ratio | 2.2 |
| Quick Ratio | 2.2 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 64.28%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 64.28% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -994.00K |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -79.95% in the last 52 weeks. The beta is 0.38, so Purple Biotech Ltd.'s price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | -79.95% |
| 50-Day Moving Average | 3.75 |
| 200-Day Moving Average | 8.61 |
| Relative Strength Index (RSI) | 48.28 |
| Average Volume (20 Days) | 901.56K |
Income Statement
In the last 12 months, Purple Biotech Ltd. had revenue of $0 and earned -$19.88M in profits. Earnings per share was $-0.09.
| Revenue | 0 |
| Gross Profit | -196.00K |
| Operating Income | 22.27M |
| Net Income | -19.88M |
| EBITDA | -22.23M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has $14.49M in cash and $351.00K in debt, giving a net cash position of $14.14M.
| Cash & Cash Equivalents | 14.49M |
| Total Debt | 351.00K |
| Net Cash | 14.14M |
| Retained Earnings | -137.45M |
| Total Assets | 35.10M |
| Working Capital | 1.48M |
Cash Flow
In the last 12 months, operating cash flow was -$19.23M and capital expenditures -$3.00K, giving a free cash flow of -$19.23M.
| Operating Cash Flow | -19.23M |
| Capital Expenditures | -3.00K |
| Free Cash Flow | -19.23M |
| FCF Per Share | -0.09 |
Margins
Gross margin is -0.1%, with operating and profit margins of 11.37K% and -10.15%.
| Gross Margin | -0.1% |
| Operating Margin | 11.37K% |
| Pretax Margin | -10.20K% |
| Profit Margin | -10.15% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
PPBT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.36% |
| FCF Yield | -195.41% |
Analyst Forecast
The average price target for PPBT is $126.5, which is 3220.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $126.5 |
| Price Target Difference | 3220.2% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Sep 17, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Sep 17, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -5.75 |
| Piotroski F-Score | 2 |